Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587961 · ClinicalTrials.gov registry record · Early Phase 1
Personalized Theratyping Trial
A Early Phase 1 study of Cystic Fibrosis, sponsored by George Solomon.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03587961: Recruiting Early Phase 1 study of Cystic Fibrosis, sponsored by George Solomon.
NCT03587961 is a Early Phase 1 study of Cystic Fibrosis that is actively recruiting participants, run by George Solomon. The registered enrollment target is 20 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03587961, a Early Phase 1 study of Cystic Fibrosis, is actively recruiting participants, sponsored by George Solomon.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
Primary Outcome
change in lung function as measured via spirometry
Conditions Studied
Interventions
- DRUG Symdeko
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2027-09-01 |
| Phase | Early Phase 1 |
What NCT03587961 shows while recruiting
NCT03587961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Symdeko is the first listed.
NCT03587961 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT03587961 about?
NCT03587961 is a clinical study titled "Personalized Theratyping Trial". The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
What is the current status of trial NCT03587961?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-08-01. Estimated completion is 2027-09-01.
What conditions does trial NCT03587961 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT03587961?
The interventions under investigation include: Symdeko (DRUG).
Who is sponsoring clinical trial NCT03587961?
This trial is sponsored by George Solomon, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03587961 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03587961's enrollment target sits among peer trials
20 130th of 169 higher than 38 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis
RECRUITING · Early Phase 1
-
Regional Monitoring of CF Lung Disease
RECRUITING · Early Phase 1
-
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240
ACTIVE NOT RECRUITING · Early Phase 1
-
19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis
COMPLETED · Early Phase 1
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI